TG Therapeutics (NASDAQ:TGTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.58) by 22.41 percent. This is a 61.36 percent decrease over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $38.00 thousand which met the analyst consensus estimate. This is the same as the same period last year.
TG Therapeutics Q4 EPS $(0.71) Misses $(0.58) Estimate, Sales $38.00K Inline
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.